28.1 C
Delhi
Wednesday, September 17, 2025

Alembic Pharma receives USFDA approval for Fulvestrant Injection

Date:

Share post:

Donate-GC-Razorpay

Mumbai: Pharma Major, Alembic Pharma on Monday said it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Prefilled Syringe.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP.

Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of breast cancer. Refer to our label for full indication.

Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US$71 million for twelve months ending September 2022, according to IQVIA.

Related articles

When Prime Minister Narendra Modi Called Me His Friend from Goa

On this special day, as Prime Minister Narendra Modi turns 75, I am reminded of my personal interaction...

Teachers Should Not Fear AI – They Should Embrace It as a Tool of Empowerment

Artificial Intelligence (AI) has become the great disruptor of our times. It is changing the way we live,...

LG Sinha flags off first dedicated parcel train from Kashmir to Delhi

Srinagar: JK Lieutenant Governor Manoj Sinha flagged off the first dedicated parcel train from Kashmir to Delhi today,...

PM Modi pays tribute to Bharat Ratna M Visvesvaraya to celebrate the Engineers’ Day

Kolkata: Prime Minister Narendra Modi today paid his heartfelt homage to Bharat Ratna M. Visvesvaraya, whose pioneering contributions...